BRCA1 and neoplasm: The implementation of the Myriad MyChoice CDx and the FoundationOne CDx in the clinic is favored by the fact that SNP-sequencing and mutational analysis of BRCA1/2 and HR-related genes are performed on DNA samples extracted from FFPE tumor tissues, generally available after primary debulking surgery or from tumor biopsies at diagnosis (14).